Current Affairs - Science
Why should I study the current affairs questions and answers section on "Science" daily?
Read the daily current affairs questions and answers section on "Science" to enhance your general knowledge for clearing competitive examinations and placement interviews.
Where can I get the current affairs questions and answers section on "Science"?
IndiaBIX provides you with daily current affairs questions and answers with explanations.
Where can I get the current affairs MCQ questions and answers section on "Science" (objective type, multiple choice)?
Here you can find multiple-choice-type current affairs questions and answers on "Science" for your interviews and competitive examinations. All the CA questions are arranged in different categories, including date-wise.
How do I download the current affairs questions section on "Science" in PDF format?
You can download the current affairs quiz questions and answers section on "Science" as PDF files or eBooks.
How do I answer the current affairs quiz section on "Science"?
You can answer any current affairs quiz question on "Science" by reading this current affairs section daily.
Exercise : Science - Latest Current Affairs
- Science - Latest Current Affairs
1.
What is the name of the world's first once-weekly basal insulin launched in India for the treatment of adult diabetes?
Answer: Option
Explanation:
Awiqli, developed by Novo Nordisk, is the world's first once-weekly basal insulin introduced in India for the treatment of adult diabetes. The medicine is designed to reduce the burden of daily insulin injections by requiring only one injection every week, reducing the annual number of injections from 365 to 52. It is administered through a pre-filled pen device and works by binding to the blood protein albumin, which creates a reservoir that releases insulin steadily over seven days. This helps maintain stable blood glucose levels and improves treatment convenience. Awiqli can be used by eligible patients with Type 2 diabetes either alone or with other medicines, while patients with Type 1 diabetes must use it together with short-acting insulin during mealtimes.
Date : 2026-07-10
2.
What is the name of India's first regulatory-approved radioligand therapy for advanced prostate cancer launched by Novartis on June 15, 2026?
Answer: Option
Explanation:
Pluvicto is India's first regulatory-approved radioligand therapy for advanced prostate cancer, launched by Novartis Healthcare Pvt Ltd. Known scientifically as lutetium-177 vipivotide tetraxetan, the therapy is specifically designed for patients with PSMA-positive metastatic prostate cancer. It combines a targeting molecule with the radioactive isotope Lutetium-177, enabling radiation to be delivered directly to cancer cells while minimising damage to healthy tissues. The treatment works by binding to Prostate-Specific Membrane Antigen (PSMA) proteins found on prostate cancer cells. This innovative therapy represents a significant advancement in precision oncology and targeted cancer treatment in India.
Date : 2026-06-17
3.
What percentage of all diseases in India is accounted for by cardiovascular diseases according to the NSO Survey 2025?
Answer: Option
Explanation:
Cardiovascular diseases have emerged as a major health concern in India, showing a significant increase over recent years. According to the NSO Survey 2025, these diseases now account for 25.6% of all reported illnesses, making them the leading category among various health conditions. This rise reflects changing lifestyles, increased stress levels, and other risk factors such as poor diet and lack of physical activity. Notably, the impact is not limited to older populations, as younger age groups are also increasingly affected. The data highlights the urgent need for improved public health strategies, awareness campaigns, and preventive healthcare measures to address this growing burden.
Date : 2026-05-04
4.
Which disease is Coartem Baby specifically developed to treat in newborns and infants?
Answer: Option
Explanation:
Malaria is the disease targeted by Coartem Baby, the first WHO-prequalified drug specifically designed for newborns and infants. Developed by Novartis in collaboration with the Medicines for Malaria Venture (MMV), this medication addresses a critical gap in pediatric treatment. It uses an artemether-lumefantrine combination and is suitable for infants weighing between 2 to 5 kilograms. The disease remains a major global health concern, causing millions of cases and deaths annually, especially among children under five in Africa, making this innovation a significant breakthrough.
Date : 2026-04-27
5.
Into how many regional languages will Ayurveda research materials be translated under the CCRAS and Anuvadini AI partnership?
Answer: Option
Explanation:
The collaboration between the Central Council for Research in Ayurvedic Sciences (CCRAS) and Anuvadini AI focuses on making Ayurveda research widely accessible by translating it into multiple regional languages. The initiative specifically targets 13 languages, including Hindi, to ensure that valuable scientific and educational content reaches a broader audience across India. This effort helps bridge linguistic barriers, making traditional medical knowledge more inclusive and understandable. By leveraging artificial intelligence, the program enhances the dissemination of authentic information, supports regional outreach, and reduces misinformation, especially in rural and linguistically diverse populations.
Date : 2026-03-31
Quick links
Quantitative Aptitude
Verbal (English)
Reasoning
Programming
Interview
Placement Papers